Axe Compute has retained Cardiff Advisory LLC to assist its Board of Directors in exploring strategic alternatives for the Helomics Business. The process may include a sale, partnership, licensing agreement, joint venture or other transactions designed to maximize shareholder value. The Helomics unit operates a CLIA-certified laboratory and biobank platform containing approximately 150,000 live and frozen tumor samples, 40,000 FFPE tissue blocks, over 200,000 pathology slides and digital images, and two decades of historical drug response data spanning 137 tumor subtypes. The strategic review underscores Axe Compute’s commitment to concentrate resources on its Aethir-powered decentralized GPU infrastructure, aiming to accelerate deployment of bare-metal AI compute services for enterprise and research customers worldwide. There is no guarantee the review will result in a transaction. The company will announce any approved course of action once its Board finalizes recommendations or deems further disclosure necessary.